Long-Term Benefits of Enhanced Secondary Prevention in ASCVD Patients

Overview

Optimizing secondary prevention by improving treatment coverage for hypertension, hypercholesterolaemia, diabetes, and smoking cessation to 70% in seven European countries could yield over 94,000 cardiovascular-event-free life-years annually. This highlights the significant potential to reduce recurrent ASCVD events and improve survival through better guideline implementation.

Background

Atherosclerotic cardiovascular disease (ASCVD) causes nearly four million deaths annually in Europe and imposes a substantial economic burden. Despite advances in acute care, mortality rates have plateaued, emphasizing the need for improved secondary prevention to reduce recurrent events such as myocardial infarction and stroke. Key modifiable risk factors include hypertension, hypercholesterolaemia, diabetes, and smoking. However, large gaps exist between guideline recommendations and real-world treatment implementation across Europe.

Data Highlights

Key Findings

• Improving treatment coverage and smoking cessation rates from approximately 43% to 70% could prevent recurrent ASCVD events and extend event-free survival.
• The SMART-REACH survival model was used to estimate lifetime benefits from modifying four key risk factors: hypertension, hypercholesterolaemia, diabetes, and smoking.
• Over 94,000 cardiovascular-event-free life-years could be gained annually across Denmark, France, Germany, Italy, Poland, Spain, and the UK.
• Germany and Italy have the highest potential gains, with over 25,000 and 21,000 life-years saved respectively.
• There is a significant implementation gap between clinical guidelines and real-world secondary prevention in Europe.
• Enhanced secondary prevention strategies could substantially reduce mortality and disability associated with ASCVD.

Clinical Implications

Clinicians should prioritize achieving guideline-recommended targets for hypertension, cholesterol, diabetes management, and smoking cessation in patients with established ASCVD. Proactive identification and timely treatment initiation are essential to close the gap between evidence-based recommendations and clinical practice. National health policies should incentivize and support these efforts to maximize cardiovascular survival gains.

Conclusion

Optimizing secondary prevention in ASCVD patients across Europe offers substantial potential to improve cardiovascular outcomes and extend event-free survival. Bridging the gap between guidelines and practice is critical to realizing these benefits at both individual and population levels.

References

1. Farley et al. 2010 -- Population-Level Impact of Treating Hypertension and Hypercholesterolaemia